CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-two analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $74.40.
A number of research firms recently weighed in on CRSP. Needham & Company LLC restated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Morgan Stanley increased their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a report on Friday, February 14th. HC Wainwright restated a "buy" rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. JMP Securities restated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target for the company in a report on Wednesday, February 12th.
Read Our Latest Analysis on CRSP
In related news, CEO Samarth Kulkarni sold 15,000 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company's stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in CRSP. Vontobel Holding Ltd. lifted its position in CRISPR Therapeutics by 3.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 16,957 shares of the company's stock valued at $797,000 after acquiring an additional 600 shares in the last quarter. nVerses Capital LLC bought a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $258,000. Blue Trust Inc. lifted its position in shares of CRISPR Therapeutics by 158.7% during the 3rd quarter. Blue Trust Inc. now owns 3,844 shares of the company's stock worth $181,000 after buying an additional 2,358 shares in the last quarter. Slow Capital Inc. lifted its position in shares of CRISPR Therapeutics by 8.5% during the 3rd quarter. Slow Capital Inc. now owns 85,910 shares of the company's stock worth $4,036,000 after buying an additional 6,694 shares in the last quarter. Finally, Eastern Bank bought a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $70,000. Institutional investors own 69.20% of the company's stock.
Shares of CRSP opened at $52.29 on Friday. CRISPR Therapeutics has a 52 week low of $36.52 and a 52 week high of $91.10. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of -18.48 and a beta of 1.67. The stock has a fifty day moving average of $41.89 and a 200-day moving average of $45.98.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. As a group, equities analysts forecast that CRISPR Therapeutics will post -5.08 EPS for the current year.
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.